New non-executive director at Amarin
This article was originally published in Scrip
Amarin (Ireland/US), a clinical-stage biopharmaceutical company focused on cardiovascular disease, has elected Jan van Heek non-executive director. As part of his board role, he has also been appointed chairman of the company's audit committee. Mr van Heek is a principal and partner at BioPoint Group, where he advises biotech and healthcare companies on commercial strategy development, financing and business development. Before that, he spent more than 18 years at Genzyme, most recently serving as senior advisor to the CEO and management team.